ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2108

Multidisciplinary Fragility Fracture Management Across Two Coordinated Hospitals: Evaluating Risk Factors, Treatment Approaches, and Long-Term Patient Outcomes in Those With and Without Prior Fractures
Abstract Number: 2109

Comparative Effects of IL-6 inhibition, Methotrexate, and Glucocorticoid Monotherapy on Bone Mineral Density, 3D-DXA femoral structure and Bone Turnover Markers in GCA and PMR
Abstract Number: 2110

Effect of Proton-Pump-Inhibitors on Bone Mineral Density and Microarchitecture in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases
Abstract Number: 2111

Cost-effectiveness Analysis of Biosimilar Denosumab for the Treatment of Women with Post-menopausal Osteoporosis in the United States: A Risk Based Analysis
Abstract Number: 2112

Which drugs are associated with the development of osteonecrosis of the jaw? clinical and epidemiological analysis of a cohort of patients diagnosed with osteonecrosis of the jaw.
Abstract Number: 2113

Mortality rate in patients with hip fracture: is it recommendable to establish fracture units?
Abstract Number: 2114

Development of a Fracture Prediction Model for Patients Aging with HIV
Abstract Number: 2115

METHOFRACT, a methotrexate osteopathy multicentric binational cohort study.
Abstract Number: 2116

Romosozumab in Multiple Myeloma Patients at High Risk of Fracture
Abstract Number: 2117

Denosumab Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis: A Multi-site Randomized Clinical Trial
Abstract Number: 2118

Risks of Fracture in Current and Previous Anticonvulsant Users, An Observational Study
Abstract Number: 2119

Fracture rates in 6475 individuals with osteogenesis imperfecta stratified by age, sex and clinical severity
Abstract Number: 2120

Analyzing Gender and Racial Disparities in Paget’s Disease of Bone: A Large-Scale Observational Study
Abstract Number: 2121

Prevention of Bone Mass Loss Associated With Aromatase Inhibitors in Breast Cancer. A Study in Real-World Clinical Practice.
Abstract Number: 2122

Safety and Efficacy of Romosozumab in the Treatment of Patients with High-Risk Fracture Osteoporosis in Clinical Practice: Experience from a Tertiary University Hospital in Spain

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].